Valneva SE

VALNEVA - Declaration of shares and voting rights - April 30, 2023

04 May 2023 12:00:00 By Nasdaq GlobeNewswire

Valneva Reports First Quarter 2023 Financial Results and Provides Corporate Updates

04 May 2023 01:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights - March 31, 2023

06 Apr 2023 02:00:00 By Nasdaq GlobeNewswire

Valneva Announces Filing of 2022 Universal Registration Document and US Form 20-F

31 Mar 2023 01:00:00 By Nasdaq GlobeNewswire

Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.

30 Mar 2023 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports Full Year 2022 Results and Provides Corporate Updates

23 Mar 2023 02:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights - February 28, 2023

06 Mar 2023 02:00:00 By Nasdaq GlobeNewswire

Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001

02 Mar 2023 01:00:00 By Nasdaq GlobeNewswire

Valneva to Present at the Cowen 43rd Annual Healthcare Conference

01 Mar 2023 11:45:00 By Nasdaq GlobeNewswire

FDA Accepts Valneva’s Chikungunya Vaccine License Application for Priority Review

20 Feb 2023 01:00:00 By Nasdaq GlobeNewswire

Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

17 Feb 2023 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports Full Year 2022 Revenue and Cash, Provides First 2023 Guidance

16 Feb 2023 01:00:00 By Nasdaq GlobeNewswire

Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

14 Feb 2023 01:00:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights - January 31, 2023

03 Feb 2023 12:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: Status on December 31, 2022 (corrected data) and January 4, 2023

19 Jan 2023 12:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: December 31, 2022

05 Jan 2023 12:00:00 By Nasdaq GlobeNewswire

Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine

30 Dec 2022 12:30:00 By Nasdaq GlobeNewswire

Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate

23 Dec 2022 01:00:00 By Nasdaq GlobeNewswire

Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum

21 Dec 2022 11:45:00 By Nasdaq GlobeNewswire

Valneva Hosts Investor Day in New York City

06 Dec 2022 01:00:00 By Nasdaq GlobeNewswire